IBA and Jubilant Radiopharma have signed a contract for the installation of five Cyclone KIUBE 180 cyclotrons in the United States, aimed at enhancing Jubilant’s PET radiopharmaceutical manufacturing capacity across key U.S. markets.

Belgium-based IBA will supply cyclotrons to support Jubilant’s $50 million expansion effort in PET radiotracer production, with applications across oncology, urology, cardiology, and neurology.

The Cyclone KIUBE 180 cyclotrons will be placed in five new PET manufacturing facilities, bringing Jubilant Radiopharma’s total PET sites to nine. Each facility will include IBA’s cyclotron, self-shielding features, and target systems, which are tailored for PET radioisotope production. This infrastructure upgrade is expected to boost the supply of PET radioisotopes, including Fluorine 18, Gallium 68, and Carbon 11, used in diagnostics and treatment monitoring for various medical conditions.
IBA’s cyclotrons are recognized for their efficiency, compact design, and flexibility in producing a range of radioisotopes. The price range for these installations, depending on customization, ranges from approximately $2.7 million to $5.4 million.

Charles Kumps, president of IBA RadioPharma Solutions, noted the strategic nature of the partnership, highlighting IBA’s commitment to providing fully GMP-compliant solutions for radiopharmaceutical production. "Our cutting-edge solutions and our expertise to integrate all necessary equipment for a fully GMP-compliant radiopharmacy will accelerate Jubilant Radiopharma’s expansion in all PET radioisotopes to advance nuclear medicine in the U.S.,” he said.

This expansion aligns with Jubilant Radiopharma’s ongoing mission to support the nuclear medicine field in the U.S., where it already operates one of the largest radiopharmacy networks.

Molecular Imaging Homepage